<p>Development and Validation of a Novel 8 Immune Gene Prognostic Signature Based on the Immune Expression Profile for Hepatocellular Carcinoma</p>
Dafeng Xu(Hainan Medical University), Jinfang Zheng(Hainan General Hospital)
Cited by 17
Related Papers
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
|The Lancet. Gastroenterology & hepatology|2025|39
Inhibition of Bone Morphogenetic Protein 2 Suppresses the Stemness Maintenance of Cancer Stem Cells in Hepatocellular Carcinoma via the MAPK/ERK Pathway
|Cancer Management and Research|2021|11